Skip to content

DaVita DVA Redeemable noncontrolling interests in subsidiaries

Redeemable noncontrolling interests in subsidiaries at other companies

UnitedHealth Group logo
UnitedHealth GroupUNH
$1.42B-67.3%
Centene logo
CenteneCNC

Other financials

Income statement

See full
Revenue$3.4B+6.0%
Operating income$481.9M+9.8%
Net income$197.5M+21.2%
EPS (diluted)$2.87+43.5%

Balance sheet

See full
Cash & equivalents$726.4M+38.5%
Total debt$13.3B+6.7%
Total equity-$755.5M-183%
Total assets$17.5B+2.2%

Cash flow

See full
Operating cash flow$320.8M+78.2%
CapEx$102.0M-28.8%
Free cash flow$218.8M+495%

Valuation

See full
Market cap$13.34B-16.0%
Enterprise value$25.95B-5.5%
P/E17.1×-1.4×
P/S-0.3×

Profitability

See full
Operating margin15.1%-0.7pp
Net margin5.6%-1.0pp
FCF margin10.8%-2.8pp

Returns & leverage

See full
Return on equity159.1%+80.9pp
Debt / equity103.6×+92.8×
Current ratio1.4×+0.2×

Where this comes from

Reported directly by DaVita in its filing.

Tagged under the XBRL concept us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount.

The official record: DaVita’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about DaVita's redeemable noncontrolling interests in subsidiaries.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is DaVita's redeemable noncontrolling interests in subsidiaries?
DaVita (DVA) reported redeemable noncontrolling interests in subsidiaries of $1.52B in Q1 2026.
How has DaVita's redeemable noncontrolling interests in subsidiaries changed year-over-year?
DaVita's redeemable noncontrolling interests in subsidiaries decreased by 8.5% year-over-year, from $1.67B to $1.52B.
What is the long-term trend for DaVita's redeemable noncontrolling interests in subsidiaries?
Over 5 years (2020 to 2025), DaVita's redeemable noncontrolling interests in subsidiaries has grown at a 2.9% compound annual growth rate (CAGR), from $1.33B to $1.53B.